Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Moelo Malahleha et al.|New England Journal of Medicine|2024Cited by 471
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension studyJared M. Baeten, Samuel Albert, Thesla Palanee‐Phillips et al.|The Lancet HIV|2021Cited by 111
Prospective study of oral pre‐exposure prophylaxis initiation and adherence among young women in KwaZulu‐Natal, South AfricaLeila E. Mansoor, Quarraisha Abdool Karim, Lara Lewis et al.|Journal of the International AIDS Society|2022Cited by 29
Integrated provision of topical pre‐exposure prophylaxis in routine family planning services in South Africa: a non‐inferiority randomized controlled trialLeila E. Mansoor, Quarraisha Abdool Karim, Nonhlanhla Yende‐Zuma et al.|Journal of the International AIDS Society|2019Cited by 18
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trialLeila E. Mansoor, Salim S. Abdool Karim, Quarraisha Abdool Karim et al.|Trials|2014Cited by 12